---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-041462"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:49:56.335695+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Judge lifts YUTREPIA injunction; Tyvaso PH-ILD exclusivity expires March 31

## Summary
- March 28: Judge Andrews set aside August 2022 injunction; FDA can now approve YUTREPIA NDA.
- March 29: Judge Bates denied United Therapeutics' motion for TRO/preliminary injunction against FDA approval.
- March 31: Regulatory exclusivity for Tyvaso in PH-ILD expired; FDA can act on YUTREPIA amended NDA.
- United Therapeutics filed appeal and new lawsuits, but none currently block YUTREPIA launch.
- Liquidia commercial team ready to launch for PAH and PH-ILD upon FDA final approval.

## SEC filing metadata
- accession: 0001104659-24-041462
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924041462/0001104659-24-041462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924041462/tm2410292d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-041462
- JSON: https://secwatch.observer/filing/0001104659-24-041462.json
- Plain text: https://secwatch.observer/filing/0001104659-24-041462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.